方法：我们研究了一组36名患有中度至重度周期性乳腺痛（平均年龄：26.0岁）的可育妇女，这些妇女表现出正常的月经史和正常的循环激素基础水平。包括催乳素（PRL），黄体生成素(LH),卵泡刺激素（FSH），雌二醇（E2），孕酮（P），睾酮（T），硫酸脱氢表雄酮(δHEAs)，雄烯二酮(A)。使用静脉注射促甲状腺激素释放激素（TRH）后连续测量PRL血浆水平，（TRH测试），患者分为两组：19例PRL对TRH反应异常，其余17例反应正常。
结果：溴隐亭治疗，2.5mgb.i.d.持续3-6个月，73.6%的TRH检测异常患者和23.5%的TRH检测正常患者有效:差异有统计学意义。另一方面,76.9％的TRH测试正常或对溴隐亭治疗耐药的患者对经皮孕酮和全身性非甾体抗炎药（NSAIDs）有良好的反应。
结论：这些结果似乎证实了以下假设，即PRL对TRH的反应可用于识别可能受益于溴隐亭治疗的周期性乳腺痛患者。
METHODS: We studied a group of 36 fertile women affected with moderate-to-severe cyclical mastalgia (mean age: 26.0 years) showing a normal menstrual history and normal basal levels of circulating hormones, including prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), progesterone (P), testosterone (T), dehydroepiandrosterone sulphate (delta HEAs),
androstenedione (A). Using serial measurements of PRL plasma levels after an intravenous injection of thyrotropin-releasing hormone (TRH), (TRH test), patients were divided in two groups: 19 patients with abnormal PRL response to TRH and the remaining 17 with normal response.
RESULTS: Bromocriptine treatment, 2.5 mg b.i.d. for 3-6 months, was effective in 73.6% of patients with abnormal TRH test and in 23.5% of patients with normal TRH test: the difference was statistically significant. On the other hand, 76.9% of patients with either normal TRH test or resistant to bromocriptine therapy had a favourable response to percutaneous progesterone and systemic non-steroidal antiinflammatory drugs (NSAIDs).
CONCLUSIONS: These results seem to confirm the hypothesis that PRL response to TRH could be used to identify patients affected with cyclical mastalgia that are likely to benefit by bromocriptine treatment.
